Q: Do your HRP-conjugated antibodies contain sodium azide?

A: No. None of our HRP-conjugated antibodies contain sodium azide as this agent inhibits the activity of HRP.

Q: How do I choose secondary antibodies to label the same cells when I have two primary antibodies from the same host?

A: Use isotype-specific secondary antibodies if the primary antibodies are of different isotypes. You can also make direct conjugates of the primary antibodies by use of antibody labeling kits, dyes, or custom conjugations (please contact Technical Support for custom orders).

Q: I am looking for a antibody that recognizes human Akt1 but NOT Akt2 or 3, for Western blot analyses. I also want that antibody to recognize Akt1 regardless of its phosphorylated form.

A: At the moment we do not have an AKT1 antibody that definitively does not react with either AKT2 or AKT3.

Q: What is the molecular weight of your antibodies?

A: All IgG antibodies are approximately 150 kDa (each heavy chain is about 50 kDa and each light chain is about 25 kDa).

Q: Why are many of your antibodies formulated with sodium azide and BSA?

A: Sodium azide is a preservative which is added to prevent bacterial growth. BSA is added as a protein stabilizer.

AKT1 Antibody (OTI4D6)

Novus Biologicals | Catalog # NBP2-01724

(1)

Citations (2)

Product Documents

View Available Conjugates View Available Formulations

100% Guarantee

Product Specifications
Scientific Data
Applications
Flow Cytometry
Preparation & Storage
Background
Product Documents
Specific Notices
Research Areas

Key Product Details

Species Reactivity

Validated:

Human, Mouse, Rat, Canine, Monkey

Cited:

Mouse, Rat

Applications

Validated:

Immunohistochemistry, Immunohistochemistry-Paraffin, Western Blot, Flow Cytometry, Immunocytochemistry/ Immunofluorescence, Simple Western

Cited:

Western Blot

Label

Unconjugated

Antibody Source

Monoclonal Mouse IgG₁ Clone # OTI4D6

View all Akt1 Primary Antibodies »

Product Specifications

Immunogen

This AKT1 antibody is made to the full length human recombinant protein of human AKT1(NP_005154) produced in HEK293T cell.

Reactivity Notes

Please note that this antibody is reactive to Mouse and derived from the same host, Mouse. Mouse-On-Mouse blocking reagent may be needed for IHC and ICC experiments to reduce high background signal. You can find these reagents under catalog numbers PK-2200-NB and MP-2400-NB. Please contact Technical Support if you have any questions.

Specificity

This antibody also cross-reacts with AKT3.

Clonality

Monoclonal

Host

Mouse

Isotype

IgG₁

Theoretical MW

55.7 kDa.
Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.

Scientific Data Images for AKT1 Antibody (OTI4D6)

Western Blot: AKT1 Antibody (OTI4D6) [NBP2-01724]

Western Blot: AKT1 Antibody (OTI4D6) [NBP2-01724] - WB analysis of extracts (35 ug) from 9 different cell lines using AKT1 antibody.

Western Blot: AKT1 Antibody (OTI4D6) [NBP2-01724]

Western Blot: AKT1 Antibody (OTI4D6) [NBP2-01724] - WB detection of AKT1 in human MD-MB-231 cells using AKT1 antibody NBP2-01724 at a dilution of 1:2000. WB image submitted by a verified customer review.

Immunocytochemistry/ Immunofluorescence: AKT1 Antibody (OTI4D6) [NBP2-01724]

Immunocytochemistry/Immunofluorescence: AKT1 Antibody (OTI4D6) [NBP2-01724] - ICC/IF of COS7 cells transiently transfected by pCMV6-ENTRY AKT1.

Western Blot: AKT1 Antibody (OTI4D6) [NBP2-01724]

Western Blot: AKT1 Antibody (OTI4D6) [NBP2-01724] - WB analysis of extracts (10 ug) from a mouse cell line and 3 different mouse tissues using AKT1 antibody at a 1:200 dilution.

Immunohistochemistry-Paraffin: AKT1 Antibody (OTI4D6) [NBP2-01724]

Immunohistochemistry-Paraffin: AKT1 Antibody (OTI4D6) [NBP2-01724] - IHC-P staining of paraffin-embedded human prostate tissue using anti-AKT1 antibody. Heat-induced epitope retrieval in 10 mM citric buffer, pH 6.0, 100C for 10 min.

Flow Cytometry: AKT1 Antibody (OTI4D6) [NBP2-01724]

Flow Cytometry: AKT1 Antibody (OTI4D6) [NBP2-01724] - Flow cytometric analysis of Jurkat cells using anti-AKT1 antibody (red), compared to a nonspecific negative control antibody (blue).

Western Blot: AKT1 Antibody (OTI4D6) [NBP2-01724]

Western Blot: AKT1 Antibody (OTI4D6) [NBP2-01724] - HEK293T cells were transfected with the pCMV6-ENTRY control (left lane) or pCMV6-ENTRY AKT1 (right lane) cDNA for 48 hrs and lysed. Equivalent amounts of cell lysates (5 ug per lane) were separated by SDS-PAGE and immunoblotted with anti-AKT1.

Immunohistochemistry-Paraffin: AKT1 Antibody (OTI4D6) [NBP2-01724]

Immunohistochemistry-Paraffin: AKT1 Antibody (OTI4D6) [NBP2-01724] - IHC-P staining of paraffin-embedded adenocarcinoma of human endometrium tissue using anti-AKT1 antibody. Heat-induced epitope retrieval in10 mM citric buffer, pH 6.0, 100C for 10 min.

Immunohistochemistry-Paraffin: AKT1 Antibody (OTI4D6) [NBP2-01724]

Immunohistochemistry-Paraffin: AKT1 Antibody (OTI4D6) [NBP2-01724] - IHC-P staining of paraffin-embedded carcinoma of human bladder tissue using anti-AKT1 antibody. Heat-induced epitope retrieval in 10 mM citric buffer, pH 6.0, 100C for 10 min.

Immunohistochemistry-Paraffin: AKT1 Antibody (OTI4D6) [NBP2-01724]

Immunohistochemistry-Paraffin: AKT1 Antibody (OTI4D6) [NBP2-01724] - IHC-P staining of paraffin-embedded carcinoma of human kidney tissue using AKT1 antibody. Heat-induced epitope retrieval in 10 mM citric buffer, pH 6.0, 100C for 10 min.

Immunohistochemistry-Paraffin: AKT1 Antibody (OTI4D6) [NBP2-01724]

Immunohistochemistry-Paraffin: AKT1 Antibody (OTI4D6) [NBP2-01724] - IHC-P staining of paraffin-embedded human kidney tissue using anti-AKT1 antibody. Heat-induced epitope retrieval in 10 mM citric buffer, pH 6.0, 100C for 10 min.

AKT1 Antibody (OTI4D6)[NBP2-01724]

AKT1 Antibody (OTI4D6)[NBP2-01724]Simple Western� analysis of endogenous protein BCAT1 from HepG2 lysates (0.5 mg/mL) using BCAT1 Mouse Monoclonal Antibody. The virtual lane view (left) shows the target (as indicated) at 1:20 dilution of primary antibody. The corresponding electropherogram view (right) plots chemiluminescence by molecular weight along the capillary at a 1:20 dilutios of primary antibody. This experiment was performed under reducing conditions on the Jess� Simple Western instrument from ProteinSimple, a Bio-Techne brand, using the 12�230 kDa Separation Module.

View 9 more images

Applications for AKT1 Antibody (OTI4D6)

Application

Recommended Usage

Flow Cytometry

1:100

Immunocytochemistry/ Immunofluorescence

1:100

Immunohistochemistry

1:150

Immunohistochemistry-Paraffin

1:150

Simple Western

1:10 - 1:250

Western Blot

1:500-2000

Application Notes

See Simple Western Antibody Database for Simple Western validation: Tested in PDLO lysate, separated by Size, antibody dilution of 1:10, 1:50, 1:250, apparent MW was 60 kDa

Reviewed Applications

Read 1 review rated 5 using NBP2-01724 in the following applications:

Western Blot (1 Review)

Flow Cytometry Panel Builder

Bio-Techne Knows Flow Cytometry

Save time and reduce costly mistakes by quickly finding compatible reagents using the Panel Builder Tool.

Advanced Features

Spectra Viewer - Custom analysis of spectra from multiple fluorochromes
Spillover Popups - Visualize the spectra of individual fluorochromes
Antigen Density Selector - Match fluorochrome brightness with antigen density

Build Your Panel Now

Formulation, Preparation, and Storage

Purification

Immunogen affinity purified

Formulation

PBS (pH 7.3), 1% BSA, 50% Glycerol

Preservative

0.02% Sodium Azide

Concentration

1 mg/ml

Shipping

The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.

Stability & Storage

Store at -20C. Avoid freeze-thaw cycles.

Background: Akt1

AKT (also known as protein kinase B (PKB) and RAC (related to A and C kinases)) is a critical intracellular serine/threonine kinase that translates signals from extracellular stimuli including growth factors, cytokines and neurotransmitters (1). AKT signaling plays critical roles in cell growth, proliferation, survival and differentiation (1). It is also involved in organogenesis, angiogenesis and metabolism. Three mammalian AKT isoforms have been identified. The AKT pathway can be activated by any of the three members who share a high level of protein homology but are independently encoded by AKT1 (PKB alpha; 14q32.32), AKT2 (PKB beta; 19q13.2), or AKT3 (PKB gamma; 1q44) (1, 2). Each AKT family member contains an N-terminal pleckstrin homology (PH) domain, a central kinase domain, and a C-terminal regulatory domain. AKT mediates many of the downstream events of phosphatidylinositol 3-kinase (PI3-K), a lipid kinase activated by growth factors, cytokines and insulin. PI3-K recruits AKT to the membrane, where it is activated by PDK1 phosphorylation. AKT has two main phosphorylation sites (Ser473 and Thr308, predicted molecular weight 56 kDa) (3, 4). Once phosphorylated, AKT dissociates from the membrane and phosphorylates targets in the cytoplasm and the cell nucleus including mammalian target of rapamycin (mTOR).

The main function of AKT is to control inhibition of apoptosis and promote cell proliferation. Survival factors can activate AKT Ser473 and Thr308 phosphorylation sites in a transcription-independent manner, resulting in the inactivation of apoptotic signaling transduction through the tumor suppressor PTEN, an antagonist to PI3-K (5). PTEN exerts enzymatic activity as a phosphatidylinositol-3,4,5-trisphosphate (PIP3) phosphatase, opposing PI3K activity by decreasing availability of PIP3 to proliferating cells, leading to overexpression and inappropriate activation of AKT noted in many types of cancer.

AKT1 function has been linked to overall physiological growth and function (2). AKT1 has been correlated with proteus syndrome, a rare disorder characterized by overgrowth of various tissues caused by a mosaic variant in the AKT1 gene in humans.

AKT2 is strongly correlated with Type II diabetes, including phenotypes of insulin resistance, hyperglycemia and atherosclerosis (2, 6).

The function of AKT3 is specifically associated to brain development, where disruptions to AKT3 are correlated with microcephaly, hemimegalencephaly, megalencephaly and intellectual disabilities (2).

References

1. Ersahin, T., Tuncbag, N., & Cetin-Atalay, R. (2015). The PI3K/AKT/mTOR interactive pathway. Mol Biosyst, 11(7), 1946-1954. doi:10.1039/c5mb00101c

2. Cohen, M. M., Jr. (2013). The AKT genes and their roles in various disorders. Am J Med Genet A, 161a(12), 2931-2937. doi:10.1002/ajmg.a.36101

3. Georgescu, M. M. (2010). PTEN Tumor Suppressor Network in PI3K-Akt Pathway Control. Genes Cancer, 1(12), 1170-1177. doi:10.1177/1947601911407325

4. Mishra, P., Paital, B., Jena, S., Swain, S. S., Kumar, S., Yadav, M. K.,... Samanta, L. (2019). Possible activation of NRF2 by Vitamin E/Curcumin against altered thyroid hormone induced oxidative stress via NFkB/AKT/mTOR/KEAP1 signalling in rat heart. Sci Rep, 9(1), 7408. doi:10.1038/s41598-019-43320-5

5. Wedel, S., Hudak, L., Seibel, J. M., Juengel, E., Oppermann, E., Haferkamp, A., & Blaheta, R. A. (2011). Critical analysis of simultaneous blockage of histone deacetylase and multiple receptor tyrosine kinase in the treatment of prostate cancer. Prostate, 71(7), 722-735. doi:10.1002/pros.21288

6. Rotllan, N., Chamorro-Jorganes, A., Araldi, E., Wanschel, A. C., Aryal, B., Aranda, J. F.,... Fernandez-Hernando, C. (2015). Hematopoietic Akt2 deficiency attenuates the progression of atherosclerosis. Faseb j, 29(2), 597-610. doi:10.1096/fj.14-262097

Long Name

v-Akt Murine Thymoma Viral Oncogene Homolog 1

Alternate Names

PKB alpha, PRKBA, RAC-alpha

Entrez Gene IDs

207 (Human)

Gene Symbol

AKT1

UniProt

P31749

Additional Akt1 Products

Product Documents for AKT1 Antibody (OTI4D6)

Download Product Datasheets

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot or batch number in the search box below.

Download SDS

Product Specific Notices for AKT1 Antibody (OTI4D6)

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Related Research Areas

Apoptosis Intracellular Kinases

Diabetic Peripheral Neuropathy

GDNF Family

Interferons

Intracellular Kinases

Notch Pathway

PDGF Family

Citations for AKT1 Antibody (OTI4D6)

Customer Reviews for AKT1 Antibody (OTI4D6) (1)

5 out of 5

1 Customer Rating

5 Stars

100%

4 Stars

3 Stars

2 Stars

1 Stars

Have you used AKT1 Antibody (OTI4D6)?

Submit a review and receive an Amazon gift card!

$25/€18/£15/$25CAN/¥2500 Yen for a review with an image

$10/€7/£6/$10CAN/¥1110 Yen for a review without an image

Submit a review

Customer Images

Showing 1 - 1 of 1 review Showing All

Filter By:

Name: Corey.

Application: Western Blot

Sample Tested: Human MD-MB-231 cells

Species: Human

Verified Customer | Posted 09/20/2013

Western Blot analysis of human MD-MB-231 cells

There are no reviews that match your criteria.

Showing 1 - 1 of 1 review Showing All

Protocols

Find general support by application which include: protocols, troubleshooting, illustrated assays, videos and webinars.

FAQs for AKT1 Antibody (OTI4D6)

Showing 1 - 5 of 5 FAQs Showing All

Q: Do your HRP-conjugated antibodies contain sodium azide?

A: No. None of our HRP-conjugated antibodies contain sodium azide as this agent inhibits the activity of HRP.
Q: How do I choose secondary antibodies to label the same cells when I have two primary antibodies from the same host?

A: Use isotype-specific secondary antibodies if the primary antibodies are of different isotypes. You can also make direct conjugates of the primary antibodies by use of antibody labeling kits, dyes, or custom conjugations (please contact Technical Support for custom orders).
Q: I am looking for a antibody that recognizes human Akt1 but NOT Akt2 or 3, for Western blot analyses. I also want that antibody to recognize Akt1 regardless of its phosphorylated form.

A: At the moment we do not have an AKT1 antibody that definitively does not react with either AKT2 or AKT3.
Q: What is the molecular weight of your antibodies?

A: All IgG antibodies are approximately 150 kDa (each heavy chain is about 50 kDa and each light chain is about 25 kDa).
Q: Why are many of your antibodies formulated with sodium azide and BSA?

A: Sodium azide is a preservative which is added to prevent bacterial growth. BSA is added as a protein stabilizer.
Q: Do your HRP-conjugated antibodies contain sodium azide?

A: No. None of our HRP-conjugated antibodies contain sodium azide as this agent inhibits the activity of HRP.
Q: How do I choose secondary antibodies to label the same cells when I have two primary antibodies from the same host?

A: Use isotype-specific secondary antibodies if the primary antibodies are of different isotypes. You can also make direct conjugates of the primary antibodies by use of antibody labeling kits, dyes, or custom conjugations (please contact Technical Support for custom orders).
Q: I am looking for a antibody that recognizes human Akt1 but NOT Akt2 or 3, for Western blot analyses. I also want that antibody to recognize Akt1 regardless of its phosphorylated form.

A: At the moment we do not have an AKT1 antibody that definitively does not react with either AKT2 or AKT3.
Q: What is the molecular weight of your antibodies?

A: All IgG antibodies are approximately 150 kDa (each heavy chain is about 50 kDa and each light chain is about 25 kDa).
Q: Why are many of your antibodies formulated with sodium azide and BSA?

A: Sodium azide is a preservative which is added to prevent bacterial growth. BSA is added as a protein stabilizer.
Q: Do your HRP-conjugated antibodies contain sodium azide?

A: No. None of our HRP-conjugated antibodies contain sodium azide as this agent inhibits the activity of HRP.
Q: How do I choose secondary antibodies to label the same cells when I have two primary antibodies from the same host?

A: Use isotype-specific secondary antibodies if the primary antibodies are of different isotypes. You can also make direct conjugates of the primary antibodies by use of antibody labeling kits, dyes, or custom conjugations (please contact Technical Support for custom orders).
Q: I am looking for a antibody that recognizes human Akt1 but NOT Akt2 or 3, for Western blot analyses. I also want that antibody to recognize Akt1 regardless of its phosphorylated form.

A: At the moment we do not have an AKT1 antibody that definitively does not react with either AKT2 or AKT3.
Q: What is the molecular weight of your antibodies?

A: All IgG antibodies are approximately 150 kDa (each heavy chain is about 50 kDa and each light chain is about 25 kDa).
Q: Why are many of your antibodies formulated with sodium azide and BSA?

A: Sodium azide is a preservative which is added to prevent bacterial growth. BSA is added as a protein stabilizer.
Q: Do your HRP-conjugated antibodies contain sodium azide?

A: No. None of our HRP-conjugated antibodies contain sodium azide as this agent inhibits the activity of HRP.
Q: How do I choose secondary antibodies to label the same cells when I have two primary antibodies from the same host?

A: Use isotype-specific secondary antibodies if the primary antibodies are of different isotypes. You can also make direct conjugates of the primary antibodies by use of antibody labeling kits, dyes, or custom conjugations (please contact Technical Support for custom orders).
Q: I am looking for a antibody that recognizes human Akt1 but NOT Akt2 or 3, for Western blot analyses. I also want that antibody to recognize Akt1 regardless of its phosphorylated form.

A: At the moment we do not have an AKT1 antibody that definitively does not react with either AKT2 or AKT3.
Q: What is the molecular weight of your antibodies?

A: All IgG antibodies are approximately 150 kDa (each heavy chain is about 50 kDa and each light chain is about 25 kDa).
Q: Why are many of your antibodies formulated with sodium azide and BSA?

A: Sodium azide is a preservative which is added to prevent bacterial growth. BSA is added as a protein stabilizer.
Q: Do your HRP-conjugated antibodies contain sodium azide?

A: No. None of our HRP-conjugated antibodies contain sodium azide as this agent inhibits the activity of HRP.
Q: How do I choose secondary antibodies to label the same cells when I have two primary antibodies from the same host?

A: Use isotype-specific secondary antibodies if the primary antibodies are of different isotypes. You can also make direct conjugates of the primary antibodies by use of antibody labeling kits, dyes, or custom conjugations (please contact Technical Support for custom orders).
Q: I am looking for a antibody that recognizes human Akt1 but NOT Akt2 or 3, for Western blot analyses. I also want that antibody to recognize Akt1 regardless of its phosphorylated form.

A: At the moment we do not have an AKT1 antibody that definitively does not react with either AKT2 or AKT3.
Q: What is the molecular weight of your antibodies?

A: All IgG antibodies are approximately 150 kDa (each heavy chain is about 50 kDa and each light chain is about 25 kDa).
Q: Why are many of your antibodies formulated with sodium azide and BSA?

A: Sodium azide is a preservative which is added to prevent bacterial growth. BSA is added as a protein stabilizer.